Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

Incyte Corporation (INCY) reported first-quarter 2024 adjusted earnings of 64 cents per share, which missed the Zacks Consensus Estimate of 88 cents. The company had recorded earnings of 37 cents per share in the year-ago quarter.Total revenues in the reported quarter were $881 million, which grew 9% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line, however, missed the Zac ...